A phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic study of PM00104 [Zalypsis] administered intravenously over 1 hour daily for 5 days, every 3 weeks, to subjects with advanced malignant solid tumors or lymphoma
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2008
At a glance
- Drugs PM 00104 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 15 Oct 2008 Status changed from recruiting to discontinued, as reported by Clinicaltrials.gov.
- 07 Nov 2006 New trial record.